Susquehanna Portfolio Strategies, LLC
Position in FATE — Fate Therapeutics Inc
CIK 1996449
Bala Cynwyd, PA
Position in FATE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$912,756
New position
Shares Held
338,058
first reported quarter
Ownership
0.282%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#32
of 156 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Susquehanna Portfolio Strategies, LLC holds $404,884,857 across 122 Biotechnology names. FATE ranks #72 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
90,928 | $45,166,665 | |
| 2 | MRNA |
Moderna, Inc.
|
471,043 | $32,987,141 | |
| 3 | CORT |
Corcept Therapeutics Inc
|
211,017 | $18,347,928 | |
| 4 | BBIO |
BridgeBio Pharma, Inc.
|
226,869 | $16,897,203 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
273,562 | $15,653,217 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
166,503 | $13,032,189 | |
| 7 | EXEL |
Exelixis, Inc.
|
229,749 | $12,500,643 | |
| 8 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
22,003 | $11,814,510 |
All Filings in FATE
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $912,756 | 338,058 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||